

Substitute for form 1449A/PTO

ATTORNEY'S DKT NO.
032775-041APPLICATION NO.
09/847,356INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Donald Morris, et al.FILING DATE
May 3, 2001GROUP
1633 1642

JUL 31 2001


 RECEIVED
 AUG 1 2001
 TECH CENTER 1500/2000

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
Amh	6,136,307		Lee, et al.	10-24-00


FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
Amh	WO 99/08692		WO	02-25-1999		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
Amh	Armstrong, G.D. et al., "Studies on reovirus receptors of L cells: virus binding characteristics and comparison with reovirus receptors of erythrocytes", <i>Virology</i> 138:37: 37-48 (1984).
	✓ Bensinger, W.I., "Should we purge?", <i>Bone Marrow Transplant.</i> 21: 113-115 (1998).
	✓ Bos, J.L., "Ras Oncogenes in Human Cancer: A Review", <i>Canc. Res.</i> 49(17): 4682-4689 (1989).
	✓ Chandron and Nibert, "Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subviral particle", <i>J. of Virology</i> 72(1):467-75 (1998).
	✓ Coffey, M.C., et al., "Reovirus therapy of tumors with activated Ras pathway", <i>Science</i> 282: 1332-1334 (1998).
q	Duggan, P.R., et al., "Predictive factors for long-term engraftment of autologous blood stem cells", <i>Bone Marrow Transplantation</i> 26(12): 1299-1304 (2000).
	✓ Gao, J., B. Tombal and J.T. Isaacs, "Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and <i>in vitro</i> cultures from such xenografts", <i>Prostate</i> 39(1): 67-70, 1999.
	✓ Gentsch, J.R.K. and Pacitti, A.F., "Effect of neuraminidase treatment of cells and effect of soluble glycoproteins of type 3 reovirus attachment to murine L cells", <i>J. Virol.</i> 56:356: 356-64 (1985).
	✓ Neito, Y. and E.J. Shpall, "Autologous stem-cell transplantation for solid tumors in adults", <i>Hematol. Oncol. Clin. North Am.</i> 13(5): 939-968 (1999).
	✓ Norman, K. and P. Lee, "Reovirus as a novel oncolytic agent", <i>J. Clin. Invest.</i> 105 (8): 1035-1038 (2000).
	✓ Paul R.W. et al., "The alpha-anameric form of sialic acid is the minimal receptor determinant recognized by reovirus", <i>Virology</i> 172: 382-385 (1989).
q	Spyridonidis, A. et al., "Minimal residual disease in autologous hematopoietic harvests from breast cancer patients", <i>Annals of Oncology</i> 9: 821-826 (1998).
q	Stewart, D.A., et al., "Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens", <i>Bone Marrow Transplant.</i> 23(2): 111-117 (1999).
q	Strong, J.E., et al., "The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus", <i>EMBO J.</i> 17: 3351-3362 (1998).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



SHEET 2 OF 2

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTORNEY'S DKT NO. 032775-041	APPLICATION NO. 09/847,356
	APPLICANT Donald Morris, et al.	
	FILING DATE May 3, 2001	GROUP 1633 1642

amb ✓	Strong, J.E. and P.W. Lee, "The v-erb V oncogene confers enhanced cellular susceptibility to reovirus infection", <i>J. Virol.</i> 70 : 612-616 (1996).		
J ✓	Strong, J.E., et al., "Evidence that the Epidermal Growth Factor Receptor on Host Cells Confers Reovirus Infection Efficiency", <i>Virology</i> 197 (1): 405-411 (1993).		
J ✓	Winter, J.N., "High-dose therapy with stem-cell transplantation in the malignant lymphomas", <i>Oncology (Huntingt)</i> 13 (12): 1635-1645 (1999).		
Examiner Signature	amb Harris	Date Considered	4/1/2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.